Seattle-based Athira Pharma closed on a Series B financing worth $85 million, led by Perceptive Advisors.
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’ pipeline products.
The U.S. Food and Drug Administration granted approval to Seattle Genetics Inc.’s Tukysa tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
Stuart Hughes was named CEO of Pathios Therapeutics Ltd.
Researchers at the University of Helsinki identified a molecule called BT13 that potentially can increase levels of dopamine.
A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.
An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.
The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
Acceleron Pharma and Fulcrum Therapeutics enter 2020 as partners to tackle pulmonary diseases.
